文献速递甲状腺疾病

放射性碘难治性分化型甲状腺癌的临床、病理及分子特征分析

Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2019-01-01

本研究回顾性分析两中心2013-2017年甲状腺癌患者数据,比较54例放射性碘难治(RAIR)患者与22例性别年龄匹配对照。RAIR组累计放射碘剂量更高(518 mCi vs 302 mCi,p=0.002),治疗次数更多(2.2 vs 1.3,p=0.001)。年龄>46岁者RAIR风险增高(OR 4.5),白种人风险降低(OR 0.33,p=0.079)。分子分析显示50%RAIR患者携带RAS/RAF通路突变。

要点

  • RAIR患者与RAI敏感者在肿瘤大小、局灶侵犯、甲状腺外侵犯及组织学上无显著差异。
  • RAIR组累计放射碘剂量及治疗次数显著高于对照组。
  • 年龄>46岁与RAIR风险增高相关,白种人风险降低。

核心结论

  • 转移性分化型甲状腺癌中,RAIR患者的组织病理学和临床特征与RAI敏感患者相似。
  • 年龄≥46岁增加RAIR风险,白种人风险降低。

研究设计与样本

  • 回顾性分析两所三级医疗中心2013-2017年甲状腺癌患者数据。
  • RAIR组54例,对照组22例为性别年龄匹配且随访至少3年疾病稳定或消退者。
  • 对部分RAIR患者进行分子谱分析。

主要发现

  • RAIR组平均年龄57岁(SD=13),男性占56%(对照组41%),平均肿瘤大小4 cm(SD=2.5)。
  • RAIR组多灶性54%,手术切缘受累42%,局灶侵犯79%,甲状腺外侵犯61%。
  • RAIR组累计放射碘剂量518 mCi vs 对照组302 mCi(p=0.002),治疗次数2.2 vs 1.3(p=0.001)。
  • RAIR组50%(11/22)携带RAS/RAF通路突变;19例中 median tumor mutational burden 5 megabase(范围3-16),26%(5/19)PD-L1强阳性。

关键数值与推荐

  • RAIR定义依据美国甲状腺协会指南。
  • 年龄>46岁者RAIR的OR为4.5;白种人OR为0.33(p=0.079)。
  • 肿瘤大小、局灶侵犯、甲状腺外侵犯及组织学在RAIR与对照组间无统计学显著差异。

临床怎么用

  • 对转移性分化型甲状腺癌患者,应结合年龄和种族评估RAIR风险。
  • RAIR患者接受更高累计放射碘剂量和更多治疗次数,需关注相关毒性。
  • 分子检测可识别RAS/RAF通路突变及PD-L1状态,可能指导靶向治疗。

局限性

  • 回顾性研究设计。
  • RAIR组样本量较小(54例),对照组22例。
  • 分子谱分析仅 subset 患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Six to 20% of thyroid cancer (TC) patients develop distant metastases, and one-third become radioiodine refractory (RAIR). Available targeted therapies increase progression-free survival but are associated with toxicities. This study aims to characterize clinical, pathological, and molecular profiles of patients with RAIR TC. Methods: Data of TC patients seen during 2013-2017 at two tertiary care centers were retrospectively analyzed. Patients were considered RAIR according to American Thyroid Association guidelines. The control cohort was sex matched and age matched and had either regression or stable disease (by Response Evaluation Criteria in Solid Tumors) on follow-up at least three years after initial therapy. Molecular profiles on a subset of RAIR patients were reviewed. Results: Compared with 22 matched controls, 54 RAIR patients had an average age of 57 years (standard deviation [SD] = 13), 56% were male (41% in the control group); the average tumor size was 4 cm (SD = 2.5); tumors were multifocal in 54%, with involved surgical margins in 42%, focal invasion in 79%, and extrathyroidal extension (ETE) in 61%. Sixty-six percent had distant metastases at initial presentation with metastases to the lungs in 85%, bone in 56%, both sites in 43%, brain in 9%, and liver in 4%. There were no statistically significant differences between RAIR and controls in tumor size, focal invasion, ETE, and histology. The RAIR group received a higher cumulative radioactive iodine (RAI) dose and number of therapies compared with the controls (518 mCi vs. 302 mCi, p = 0.002 and 2.2 vs. 1.3 treatments, p = 0.001). Overall, patients >46 years had 4.5 times higher odds ratio (OR) of being RAIR; white race/ethnicity was associated with a reduced OR of RAIR disease (OR 0.33, p = 0.079). Molecular profiling data in the RAIR subgroup indicated that 50% of patients harbored mutations in the RAS/RAF pathway (11/22). Among 19 patients with a more extensive molecular panel, median tumor mutational burden was 5 megabase (range 3-16) and 26% (5/19) exhibited strong PD-L1 positivity. Conclusion: Among patients with metastatic differentiated thyroid carcinomas, patients with RAIR have similar histopathological and clinical characteristics as patients with RAI avid cancer. The risk of having RAIR TC is increased at age ≥46 and reduced in Caucasians.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Shobab L, Gomes-Lima C, Zeymo A, et al. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid. 2019. PMID: 31319763. doi:10.1089/thy.2019.0075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。